Square Pharmaceuticals PLC., together with its subsidiaries, manufactures, markets, and sells pharmaceutical products in Bangladesh and internationally. The company offers pharmaceutical products comprising alimentary preparations, amoebocides, analgesics, anti-aphthous ulcer, anti-erectile dysfunction, anti-gout, anti-hyperkalemia, anti-osteoarthritis, anti-thyroid, anti-ulcerants, anthelmintics, antiallergies, antianemics, antiasthma, antibiotics, antidiabetics, antifibrinolytics, antihemorrhoidals, antihistamines, antiosteoporotics, antioxidants, antiparasites, aromatase inhibitors, bone calcium regulators, erythropoiesis stimulating agents, gynae anti-infectives, magnesium, mineral supplements, non-narcotic analgesics, non-hormonals, non-steroidal anti-inflammatory drugs, antibacterials, vitamins, prolactin inhibitors, selective serotonin reuptake inhibitors, anti-rheumatic agents, steroids, antifungals, antivirals, antiprotozoals, topical ear and nasal preparations, and skin and urological preparations; and generic pharmaceuticals, infusions, lubricants, laxatives, and mouthwash. It also provides pharmaceuticals for cardiovascular, CNS, cough and cold, dialysis, digestive enzymes, eyes, hepatobiliary disorders, hyperphosphatemia, hypoactive sexual desire, inflammatory bowel, oncology, and respiratory tract infections. In addition, the company offers basic chemicals; herbal and nutraceutical; animal health; and crop care products, such as agricultural chemicals and insecticides; and reusable insulin pens under the AnsuPen brand. It exports its products to approximately 42 countries. The company was founded in 1958 and is headquartered in Dhaka, Bangladesh. Square Pharmaceuticals PLC. is a subsidiary of Square Group.
Metrics to compare | SQPH | Peers Peers - average of corresponding metrics from companies closely matching SQPH: ACMELAB, BXPHARMA, ADVENT, CENTRALPHL, TECHNODRUG | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSQPHPeersSector |
---|---|---|---|---|
P/E Ratio | 7.8x | 14.1x | −0.4x | |
PEG Ratio | 0.49 | −0.65 | 0.00 | |
Price/Book | 1.4x | 0.8x | 2.6x | |
Price / LTM Sales | 2.4x | 2.2x | 2.9x | |
Upside (Analyst Target) | 55.1% | 41.1% | 51.7% | |
Fair Value Upside | Unlock | 9.4% | 9.5% | Unlock |